Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-048/00
A61K-035/00
출원번호
US-0043808
(2005-01-25)
등록번호
US-7307066
(2007-12-11)
발명자
/ 주소
Sallberg,Matti
출원인 / 주소
Tripep AB
대리인 / 주소
Knobbe Martens Olson & Bear LLP
인용정보
피인용 횟수 :
5인용 특허 :
77
초록▼
Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making
Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
대표청구항▼
What is claimed is: 1. An immunogenic composition comprising a purified or isolated nucleic acid that comprises at least 200 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof and an adjuvant. 2. The composition of claim 1, wherein said nucleic acid comprises at
What is claimed is: 1. An immunogenic composition comprising a purified or isolated nucleic acid that comprises at least 200 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof and an adjuvant. 2. The composition of claim 1, wherein said nucleic acid comprises at least 500 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof. 3. The composition of claim 1, wherein said nucleic acid comprises the sequence of SEQ. ID. NO.: 35. 4. The composition of claim 1, wherein said nucleic acid consists essentially of the sequence of SEQ ID NO: 35. 5. The composition of claim 1, wherein said nucleic acid consists of the sequence of SEQ. ID. NO.: 35. 6. The composition of claim 1, wherein said nucleic acid is a vector that comprises at least 200 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof. 7. The composition of claim 1, further comprising a pharmaceutically acceptable carrier. 8. The composition of claim 1, wherein said composition is formulated for use with an electrical injection device. 9. The composition of claim 8, wherein said electrical injection device is a needleless injection device. 10. The composition of claim 1, wherein said purified or isolated nucleic acid is associated with an injection device. 11. The composition of claim 10, wherein said nucleic acid comprises at least 500 consecutive nucleotides of the sequence of SEQ ID NO: 35 or the complement thereof. 12. The composition of claim 10, wherein said nucleic acid comprises the sequence of SEQ. ID. NO.: 35. 13. The composition of claim 10, wherein said nucleic acid consists of the sequence of SEQ. ID. NO.: 35. 14. The composition of claim 1, wherein said composition is formulated for transdermal administration. 15. The composition of claim 1, wherein said composition is formulated for intranasal administration. 16. The composition of claim 10, wherein said device is needleless. 17. The composition of claim 2, wherein said composition is formulated for use with an electrical injection device. 18. The composition of claim 17, wherein said electrical injection device is a needleless injection device. 19. The composition of claim 3, wherein said composition is formulated for use with electrical injection device. 20. The composition of claim 19, wherein said electrical injection device is a needleless injection device. 21. The composition of claim 5, wherein said composition is formulated for use with an electrical injection device. 22. The composition of claim 21, wherein said electrical injection device is a needleless injection device. 23. The composition of claim 11, wherein said device is electrical. 24. The composition of claim 11, wherein said device is needleless. 25. The composition of claim 12, wherein said device is electrical. 26. The composition of claim 12, wherein said device is needleless. 27. The composition of claim 13, wherein said device is electrical. 28. The composition of claim 13, wherein said device is needleless. 29. An immunogenic composition comprising a purified or isolated nucleic acid that comprises at least 200 consecutive nucleotides of the sequence of SEQ ID NO: 35 or the complement thereof and ribavirin. 30. The composition of claim 29, wherein said purified or isolated nucleic acid comprises at least 500 consecutive nucleotides of the sequence of SEQ ID NO: 35 or the complement thereof. 31. The composition of claim 29, wherein said purified or isolated nucleic acid consists essentially of the sequence of SEQ ID NO: 35 or the complement thereof. 32. The composition of claim 29, wherein said purified or isolated nucleic acid consists of the sequence of SEQ ID NO: 35 or the complement thereof. 33. The composition of claim 29, wherein said composition is formulated for use with an electrical injection device. 34. The composition of claim 29, wherein said electrical injection device is a needleless injection device. 35. The composition of claim 29, wherein said composition is formulated for transdermal administration. 36. The composition of claim 29, wherein said composition is formulated for intranasal administration. 37. A method of making the composition of claim 1 comprising: providing a purified or isolated nucleic acid that comprises at least 200 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof; and mixing said nucleic acid with an adjuvant so as to make the composition of claim 1. 38. The method of claim 37, wherein said nucleic acid comprises at least 500 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof. 39. The method of claim 37, wherein said nucleic acid comprises the sequence of SEQ. ID. NO.: 35. 40. The method of claim 37, wherein said nucleic acid consists of the sequence of SEQ. ID. NO.: 35. 41. The method of claim 37, wherein said nucleic acid is a vector that comprises at least 200 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof. 42. The method of claim 37, wherein said nucleic acid consists essentially of the sequence of SEQ ID NO: 35. 43. A method of using the composition of claim 1 to an immune response to a hepatitis C antigen comprising: providing the composition of claim 1 to an animal in need of an immune response to a hepatitis C antigen. 44. The method of claim 43, wherein said nucleic acid comprises at least 500 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof. 45. The method of claim 43, wherein said nucleic acid comprises the sequence of SEQ. ID. NO.: 35. 46. The method of claim 43, wherein said nucleic acid consists of the sequence of SEQ. ID. NO.: 35. 47. The method of claim 43, wherein said nucleic acid is a vector that comprises at least 200 consecutive nucleotides of the sequence of SEQ. ID. NO.: 35 or the complement thereof. 48. The method of claim 43, wherein said nucleic acid consists essentially of the sequence of SEQ ID NO: 35. 49. The method of claim 43, further comprising measuring the levels of HCV antigen-specific IgG in said animal. 50. The method of claim 43, further comprising identifying an animal in need of an increase in mean antibody titer against an HCV specific antigen. 51. The method of claim 43, further comprising identifying an animal in need of an increase in a proliferative T cell response to an HCV specific antigen. 52. The method of claim 44, further comprising measuring the levels of HCV antigen-specific IgG in said animal. 53. The method of claim 44, further comprising identifying an animal in need of an increase in mean antibody titer against an HCV specific antigen. 54. The method of claim 44, further comprising identifying an animal in need of an increase in a proliferative T cell response to an HCV specific antigen. 55. The method of claim 45, further comprising measuring the levels of HCV antigen-specific IgG in said animal. 56. The method of claim 45, further comprising identifying an animal in need of an increase in mean antibody titer against an HCV specific antigen. 57. The method of claim 45, further comprising identifying an animal in need of an increase in a proliferative T cell response to an HCV specific antigen. 58. The method of claim 46, further comprising measuring the levels of HCV antigen-specific IgG in said animal. 59. The method of claim 46, further comprising identifying an animal in need of an increase in mean antibody titer against an HCV specific antigen. 60. The method of claim 46, further comprising identifying an animal in need of an increase in a proliferative T cell response to an HCV specific antigen. 61. The method of claim 47, further comprising measuring the levels of HCV antigen-specific lgG in said animal. 62. The method of claim 44, further comprising measuring the levels of HCV antigen-specific IgG in said animal. 63. The method of claim 48, further comprising measuring the levels of HCV antigen-specific IgG in said animal. 64. The method of claim 48, further comprising identifying an animal in need of an increase in mean antibody titer against an HCV specific antigen. 65. The method of claim 48, further comprising identifying an animal in need of an increase in a proliferative T cell response to an HCV specific antigen. 66. The method of claim 49, further comprising identifying an animal in need of an increase in mean antibody titer against an HCV specific antigen. 67. The method of claim 49, further comprising identifying an animal in need of an increase in a proliferative T cell response to an HCV specific antigen. 68. A method of using the composition of claim 29 to promote an immune response to a hepatitis C viral antigen comprising: providing the composition of claim 29 to an animal in need of an immune response to a hepatitis C viral antigen. 69. The method of claim 68, further comprising measuring the HCV-specific antibody titer in said animal. 70. The method of claim 68, further comprising identifying an animal in need of an in mean antibody titer against an HCV-specific antigen. 71. The method of claim 68, further comprising identifying an animal in need of an increase in a proliferative T cell response to an HCV-specific antigen. 72. The method of claim 69, further comprising identifying an animal in need of an in mean antibody titer against an HCV-specific antigen. 73. The method of claim 69, further comprising identifying an animal in need of an increase in a proliferative T cell response to an HCV-specific antigen.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (77)
Houghton Michael ; Choo Qui-Lim ; Kuo George, Antibody compositions to HCV and uses thereof.
Houghton Michael (Danville CA) Choo Qui-Lim (El Cerrito CA) Kuo George (San Francisco CA), Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies.
Ralston Robert O. ; Marcus Frank ; Thudium Kent B. ; Gervase Barbara A. ; Hall John A. ; Berger Kim M. ; Choo Oui-Lim ; Houghton Michael ; Kuo George, Hepatitis C virus asialoglycoproteins.
Ralston Robert O. ; Marcus Frank ; Thudium Kent B. ; Gervase Barbara A. ; Hall John A. ; Berger Kim M. ; Choo Qui-Lim ; Houghton Michael ; Kuo George, Hepatitis C virus asialoglycoproteins.
Ralston Robert O. ; Marcus Frank ; Thudium Kent B. ; Gervase Barbara A. ; Hall John A. ; Berger Kim M. ; Choo Qui-Lim ; Houghton Michael ; Kuo George, Hepatitis C virus asialoglycoproteins.
Ralston Robert O. ; Marcus Frank ; Thudium Kent B. ; Gervase Barbara A. ; Hall John A. ; Berger Kim M. ; Choo Qui-Lim ; Houghton Michael ; Kuo George, Hepatitis C virus asialoglycoproteins.
Miyamura Tatsuo,JPX ; Saito Izumi,JPX ; Houghton Michael ; Weiner Amy J. ; Han Jang ; Kolberg Janice A. ; Cha Tai-An ; Irvine Bruce D., Hepatitis C virus isolate polypeptides.
Miyamura Tatsuo (Tokyo JPX) Saito Izumi (Tokyo CA JPX) Houghton Michael (Danville CA) Weiner Amy J. (Benicia CA) Han Jang (Lafayette CA) Kolberg Janice A. (Hercules CA) Cha Tai-An (San Ramon CA) Irvi, Hepatitis C virus isolates.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Pirrung Michael C. (Durham NC) Read J. Leighton (Palo Alto CA) Fodor Stephen P. A. (Palo Alto CA) Stryer Lubert (Stanford CA), Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof.
Houghton Michael ; Choo Qui-Lim ; Kuo George ; Weiner Amy J. ; Han Jang ; Urdea Michael Steven ; Irvine Bruce Duncan ; Kolberg Janice A., Methods for detecting Hepatitis C virus using polynucleotides specific for same.
Houghton Michael ; Choo Qui-Lim ; Kuo George ; Weiner Amy J. ; Han Jang ; Urdea Michael Steven ; Irvine Bruce Duncan ; Kolberg Janice A., NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus.
Brechot Christian,FRX ; Kremsdorf Dina,FRX ; Porchon Colette,FRX, Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Gelfand David H. (Oakland CA) Horn Glenn (Emeryville CA) Saiki Randall K. (Richmond CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
McGall Glenn H. (Mountain View CA) Fodor Stephen P. A. (Palo Alto CA) Sheldon Edward L. (Menlo Park CA), Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.